Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $216.00

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price raised by Mizuho from $212.00 to $216.00 in a research note published on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock. Other analysts have also issued reports about the company. Royal Bank of Canada lifted their price objective on Axsome […]

Leave a Reply

Your email address will not be published.

Previous post CollPlant Biotechnologies’ (CLGN) Buy Rating Reaffirmed at D. Boral Capital
Next post Morgan Stanley Reaffirms “Underweight” Rating for Helmerich & Payne (NYSE:HP)